In conclusion, we propose that KLK1, KLK2, KLK3 KLK4, KLK8, KLK9, and KLK14, which are differentially expressed in prostate cancer, could be used as promising biomarkers of prostate cancer progression. The gene discussed is KLK3; the disease is prostate carcinoma.